PDT Partners LLC Purchases New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

PDT Partners LLC acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the third quarter, Holdings Channel reports. The institutional investor acquired 37,110 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,157,000.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Innealta Capital LLC bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $72,000.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.

Insider Activity

In other news, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now owns 926,172 shares in the company, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,213 shares of company stock valued at $5,660,180. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Down 1.1 %

Shares of Supernus Pharmaceuticals stock opened at $36.57 on Monday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37. The company has a market capitalization of $2.02 billion, a PE ratio of 34.18 and a beta of 0.86. The stock’s fifty day moving average is $34.20 and its two-hundred day moving average is $31.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm’s revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.29) EPS. As a group, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.